190,000 downloads from SpringerLink and PubMed! A selection of the most highly read articles for the journal in 2018 include: During the previous year, we have continued promoting Plain Language Summaries to authors, and have published articles with these. Plain Language Summaries are published as part of the article, beneath the abstract, and their purpose is to assist non-experts (including nonspecialists, patients, caregivers and others) in understanding important medical advances. An example published in Cardiology and Therapy in 2018 can be seen here: https://link.springer. com/article/10.1007/s40119-018-0110-5.
Our increasing presence on social media has been a particular highlight also, and the journal's Twitter account (@Cardio_Therapy) now boasts over 370 followers. Tweets are sent out when articles are published online in the journal, and during conferences and relevant cardiology days.
As we look to the year ahead, the main topics of interest are listed by all three of our Editor in Chiefs below.
Ian Menown predicts there to be interest in antiplatelet duration post-percutaneous coronary intervention with regards to when and how to go short, and when to prolong. Other topics of relevance include the role of low-dose rivaroxaban 2.5 mg bd plus aspirin for stable coronary artery disease, new guidelines and therapy options in hypertension, guideline updates in hyperlipidemia including re-evaluation of elevated triglyceride therapy options, latest data regarding inflammation and atherosclerosis, heart failure guidelines and therapy options, and the optimum antiplatelet and anticoagulant approach for patients with atrial fibrillation, elevated CHADSVASC score and recent percutaneous coronary intervention.
Robert P. Giugliano states that in 2019, we look forward to further advances in the fields of lipids, diabetes, and heart failure. New information with PCSK9 inhibitors and other lipidmodifying therapies, SGLT2 inhibitors and GLP-1 analogs, and novel treatments for heart failure are highly anticipated in the New Year. In addition, as cardiovascular medicine expands it horizons, areas such as cardio-oncology and cardio-metabolic medicine are likely to produce a wealth of exciting new data.
Uwe Zeymer thinks that the treatment of patients with left ventricular thrombus, optimal antithrombotic therapy after transcatheter aortic valve implantation, and the current status of mechanical support in cardiogenic shock will be topics of interest for the next calendar year.
In 
